our_people1.jpg

Peter Gray

Chairman

  • R
  • N

Peter Gray

Chairman

Peter Gray (65) is Chairman and non-executive director of UDG Healthcare plc. Peter formerly held senior executive positions in a number of Irish public companies, the most recent being that of Vice Chairman and Chief Executive of ICON plc, the Irish based multinational pharmaceutical development services company.

External Appointments: Peter is currently a non-executive director of Jazz Pharmaceuticals plc and a director of two venture capital backed private companies.

Peter Gray sits on the following committees:

Brendan-McAtamney.jpg

Brendan McAtamney

Chief Executive Officer

Brendan McAtamney

Chief Executive Officer

Brendan McAtamney (57) was appointed Group Chief Executive Officer on 2 February 2016, having previously served as the Group’s Chief Operating Officer since 1 September 2013. Before joining UDG Healthcare, Brendan held various senior management positions with Abbott, latterly as Vice President Commercial and Corporate Officer within the Established Pharmaceuticals division.

External Appointments:  Brendan is a non-executive director of Scapa Group plc.

Nigel-Clerkin-May2018.jpg

Nigel Clerkin

Chief Financial Officer

Nigel Clerkin

Chief Financial Officer

Nigel Clerkin (46) joined UDG Healthcare plc as Chief Financial Officer on 1 May 2018. Prior to this, Nigel held the position of CFO with ConvaTec Group plc where he worked for three years. Before this, he worked with Elan Corporation plc both in the U.S. and Europe, holding the position of Executive Vice President and CFO. Nigel started his career at KPMG and is a fellow of the Institute of Chartered Accountants of Ireland.

Chris-Brinsmead.jpg

Chris Brinsmead CBE

Non–Executive Director

  • R
  • R
  • N

Chris Brinsmead CBE

Non–Executive Director

Chris Brinsmead (60) CBE was formerly Chairman of AstraZeneca Pharmaceuticals U.K., President of AstraZeneca U.K. and Ireland and President of the Association of the British Pharmaceutical Industry (‘ABPI’). Chris held the position of Senior Independent Director of UDG Healthcare plc from 1 July 2017 until 30 April 2019.

External Appointments: Chris joined Consort Medical plc as a non-executive director in February 2019 and became Chairman in April 2019. Chris is also Chair of Collagen Solutions plc and is a member of the Council at Imperial College.

Chris Brinsmead CBE sits on the following committees:

Linda-Wilding.jpg

Linda Wilding

Non-Executive Director

  • A
  • R
  • N

Linda Wilding

Non-Executive Director

Linda Wilding’s (60) career includes 12 years at Mercury Asset Management where she held the position of Managing Director in the Private Equity division. Prior to this, Linda qualified as a chartered accountant while working with Ernst & Young.

External Appointments: Linda is a non-executive director of BMO Commercial Property Trust, Foreign & Colonial Commercial Property and the Wesleyan Assurance Society.

Linda Wilding sits on the following committees:

Myles-Lee-April-2017teal.jpg (1)

Myles Lee

Senior Independent Director

  • A
  • N

Myles Lee

Senior Independent Director

Myles (66) was Group Chief Executive of CRH plc, a FTSE 100 and Fortune 500 company, prior to retiring in December 2013. With more than 30 years’ experience at senior financial and managerial level, Myles has extensive global experience in management, M&A and finance. He is a qualified civil engineer and a Fellow of the Institute of Chartered Accountants in Ireland.

External Appointments: Myles is a non-executive director of both Ingersoll-Rand Inc. and Babcock International Group plc.

Myles Lee sits on the following committees:

Lisa-Ricci.jpg

Lisa Ricciardi

Non-Executive Director

  • R
  • R

Lisa Ricciardi

Non-Executive Director

Lisa Ricciardi (59) has been CEO & Chief Business Officer with sell-side experience in VC-backed life science companies (biotech, genomics, medical devices) and buy-side experience as Global Licensing SVP of Pfizer and SVP of U.S. International and business development at Medco Health Solutions. She has led significant and transformational deals at both Pfizer and Medco. From 1 October 2019, Lisa was appointed as a Designated NED for the purposes of the New Code.

External Appointments: Lisa advises various biotechs across the industry.

Lisa Ricciardi sits on the following committees:

miller-rich-nancy.jpg

Nancy Miller-Rich

NON-EXECUTIVE DIRECTOR

  • R

Nancy Miller-Rich

NON-EXECUTIVE DIRECTOR

Nancy Miller-Rich (60) was formerly Senior Vice-President, Business Development & Licensing, Strategy and Commercial Support for Global Human Health at MSD, known as Merck in the U.S. and Canada, until her retirement in September 2017. With more than 35 years’ experience in the healthcare industry, Nancy’s background includes roles in sales, marketing and business development for MSD, Schering-Plough, Sandoz (now Novartis) and Sterling Drug.

External Appointments: Nancy is an adviser with the Gerson Lehrman Group, a director of Intercept Pharmaceuticals Inc. and executive chairman of Altum Pharma.

Nancy Miller-Rich sits on the following committees:

Chris-Corbin.jpg

Chris Corbin

Non-Executive Director

Chris Corbin

Non-Executive Director

Chris Corbin (64) retired as executive Chairman of the Ashfield division in July 2018 but has remained on the Board in a non-executive director capacity. Chris founded Ashfield Healthcare Limited. Prior to this he held sales management positions with Parke Davis, Fisons, Astra and May & Baker. Chris was formerly Patron for SETPOINT Leicestershire, Chairman of Leicestershire Business Awards and a member of Derbyshire Magistrates Bench.

External Appointments: Chris is a director of a number of privately held companies.

Erik-Van-Snippenberg.jpg

Erik Van Snippenberg

Non-Executive Director

  • A

Erik Van Snippenberg

Non-Executive Director

Erik van Snippenberg (55) spent almost 30 years with GlaxoSmithKline (‘GSK’). More recently, Erik held the position of Senior Vice President and Area Head for Europe and Canada and was a member of GSK’s Global Pharmaceutical Management Team. Prior to this, Erik held a number of senior executive roles such as Senior Vice-President and Director of U.K. and Ireland. Erik was also appointed Designated NED from 1 October 2019 for the purpose of the New Code.

External Appointments: Erik is currently a non-executive director of Eurovite Group.

Erik Van Snippenberg sits on the following committees:

Peter Chambre.jpg (1)

Peter Chambré

NON-EXECUTIVE DIRECTOR

  • R

Peter Chambré

NON-EXECUTIVE DIRECTOR

Peter (64) was Chief Executive Officer of Cambridge Antibody Group plc until 2006 and, before that, held the roles of Chief Operating Officer of Celera Genomics Group and Chief Executive Officer of Bespak plc (now Consort Medical plc). More recently, Peter was a non-executive director of Spectris plc until December 2016, and of Touchstone Innovations plc until January 2017.


External Appointments: Peter is Chairman of Immatics Biotechnologies GmbH and a Trustee of Cancer Research U.K.


 

Peter Chambré sits on the following committees:

Shane Cooke resize.jpg

Shane Cooke

NON-EXECUTIVE DIRECTOR

  • R

Shane Cooke

NON-EXECUTIVE DIRECTOR

Shane Cooke (57) was President of Alkermes plc, from September 2011 until his retirement in March 2018. Prior to this, Shane spent 10 years as Chief Financial Officer of Elan Corporation plc from 2001 and from 2007 he also was Head of Elan Drug Technologies. Prior to Elan he held the role of Chief Executive Officer of Pembroke Capital Ltd, an aviation leasing company of which he was a founder.


External Appointments: Shane serves as a non-executive director on the board of Alkermes plc, Prothena Corporation plc and Endo International plc, all publicly-quoted companies.

Shane Cooke sits on the following committees: